Captor Therapeutics Spolka Akcyjna Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Captor Therapeutics Spolka Akcyjna's earnings have been declining at an average annual rate of -39.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 68.6% per year.
Key information
-39.8%
Earnings growth rate
-38.0%
EPS growth rate
| Biotechs Industry Growth | 56.3% |
| Revenue growth rate | 68.6% |
| Return on equity | -160.7% |
| Net Margin | -523.4% |
| Next Earnings Update | 29 May 2024 |
Recent past performance updates
Recent updates
We Think Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Drive Business Growth
Mar 10
We're Not Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn
Oct 03Here's Why We're Not At All Concerned With Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Mar 13Companies Like Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Invest In Growth
Jun 15Revenue & Expenses BreakdownBeta
How Captor Therapeutics Spolka Akcyjna makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 13 | -66 | 12 | 74 |
| 30 Jun 23 | 11 | -58 | 17 | 64 |
| 31 Mar 23 | 10 | -39 | 20 | 51 |
| 31 Dec 22 | 9 | -36 | 24 | 44 |
| 30 Sep 22 | 5 | -40 | 40 | 27 |
| 30 Jun 22 | 5 | -41 | 38 | 28 |
| 31 Mar 22 | 5 | -38 | 35 | 25 |
| 31 Dec 21 | 4 | -33 | 31 | 23 |
Quality Earnings: CTX is currently unprofitable.
Growing Profit Margin: CTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CTX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: CTX has a negative Return on Equity (-160.7%), as it is currently unprofitable.